Reduced lipid metabolite abundance in human pancreatic cancer and matched serum samples following neoadjuvant FOLFIRINOX treatment
Both tumour tissue and serum samples from PDAC patients showed lower abundance of lipid metabolites following neoadjuvant FOLFIRINOX treatment. Moreover, a biomarker panel of CA 19-9 together with five serum DALs could potentially be used to assess NAT response in PDAC but requires further validation.
Authors
- Katja Benedikte Prestø Elgstøen (ORCID: https://orcid.org/0000-0002-0087-0714)
- C. Verbeke
- Helge Rootwelt (ORCID: https://orcid.org/0000-0002-5862-1745)
- Manoj Amrutkar (ORCID: https://orcid.org/0000-0002-1868-0249)
- Ivar P. Gladhaug (ORCID: https://orcid.org/0000-0003-1441-6288)
- Sander Johannes Thorbjørnsen Guttorm (ORCID: https://orcid.org/0009-0005-0775-6796)
- Knut Jørgen Labori
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
Publication Details
- Journal
- Metabolomics
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1007/s11306-025-02388-z
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kreftforeningen
- Universitetet i Oslo
- Helse Sør-Øst RHF